SFDA Activates Special Procedures For Flu Vaccine Approval
This article was originally published in PharmAsia News
Executive Summary
China's State FDA is putting in place special approval procedures to stockpile pandemic influenza vaccine before the Beijing Olympic Games opening. This is the first time that the country will enforce the procedure drawn up in 2005 to address emergency public health threats. Considering the supply urgency and the complexity of pandemic influenza vaccine R&D, SFDA is adopting an early intervention approach toward vaccine development. It has commenced approval procedures for the flu vaccine produced by Beijing Sinovac Biotech, and will complete the technical evaluation in the shortest possible time. The agency will then decide whether to issue the authorization certificate and drug approval number within three days. To date, Sinovac has finished Phase II clinical trial of its vaccine. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.